These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 9372890

  • 21. Transforming growth factor-beta1 in congenital ureteropelvic junction obstruction: diagnosis and follow-up.
    Sager C, Lopez JC, Duran V, Burek C, Perazzo E.
    Int Braz J Urol; 2009; 35(3):315-23; discussion 323-5. PubMed ID: 19538767
    [Abstract] [Full Text] [Related]

  • 22. Laparoscopic dismembered pyeloplasty for ureteropelvic junction obstruction in children.
    Kojima Y, Sasaki S, Mizuno K, Tozawa K, Hayashi Y, Kohri K.
    Int J Urol; 2009 May; 16(5):472-6. PubMed ID: 19383038
    [Abstract] [Full Text] [Related]

  • 23. Urinary epidermal growth factor, monocyte chemotactic protein-1, and β2-microglobulin in children with ureteropelvic junction obstruction.
    Bartoli F, Penza R, Aceto G, Niglio F, D'Addato O, Pastore V, Campanella V, Magaldi S, Lasalandra C, Di Bitonto G, Gesualdo L.
    J Pediatr Surg; 2011 Mar; 46(3):530-6. PubMed ID: 21376205
    [Abstract] [Full Text] [Related]

  • 24. Elevated urinary lipocalin-2, interleukin-6 and monocyte chemoattractant protein-1 levels in children with congenital ureteropelvic junction obstruction.
    Yu L, Zhou L, Li Q, Li S, Luo X, Zhang C, Wu B, Brooks JD, Sun H.
    J Pediatr Urol; 2019 Feb; 15(1):44.e1-44.e7. PubMed ID: 30420258
    [Abstract] [Full Text] [Related]

  • 25. Urinary carbohydrate antigen 19-9/creatinine ratio: A non-invasive marker for follow-up of unilateral ureteropelvic junction obstruction in children.
    Alizadeh F, Taefnia AM, Haghdani S.
    J Pediatr Urol; 2018 Feb; 14(1):62.e1-62.e4. PubMed ID: 29079483
    [Abstract] [Full Text] [Related]

  • 26. To screen or not to screen for vesicoureteral reflux in children with ureteropelvic junction obstruction: a systematic review.
    Weitz M, Schmidt M.
    Eur J Pediatr; 2017 Jan; 176(1):1-9. PubMed ID: 27888411
    [Abstract] [Full Text] [Related]

  • 27. [Prevalence of hydronephrosis and vesicoureteral reflux in pediatric urinary tract infection].
    Yoshinaga A, Morozumi M, Yamashita T, Ishii N, Matsuda T, Terao T, Hayashi T, Yamada T.
    Hinyokika Kiyo; 2007 Oct; 53(10):691-3. PubMed ID: 18018583
    [Abstract] [Full Text] [Related]

  • 28. Urinary transforming growth factor-β1 in children with obstructive uropathy.
    Zieg J, Blahova K, Seeman T, Bronsky J, Dvorakova H, Pechova M, Janda J, Matousovic K.
    Nephrology (Carlton); 2011 Aug; 16(6):595-8. PubMed ID: 21382126
    [Abstract] [Full Text] [Related]

  • 29. MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy.
    Grandaliano G, Gesualdo L, Bartoli F, Ranieri E, Monno R, Leggio A, Paradies G, Caldarulo E, Infante B, Schena FP.
    Kidney Int; 2000 Jul; 58(1):182-92. PubMed ID: 10886563
    [Abstract] [Full Text] [Related]

  • 30. Does preoperative screening VCUG affect the outcomes and complications of pyeloplasty in patients with ureteropelvic junction obstruction?
    Suarez Arbelaez MC, Khanna K, Raymo A, Weber A, Lerendegui L, Nackeeran S, Gosalbez R, Labbie AS, Castellan MA, Nassau DE, Alam A.
    J Pediatr Urol; 2024 Feb; 20(1):76.e1-76.e7. PubMed ID: 37839944
    [Abstract] [Full Text] [Related]

  • 31. [The coexistence of vesicoureteral reflux and ureteropelvic junction obstruction in children].
    Tsai TC, Huang FY, Chang PY, Hsu CC, Chang HK, Chen CC.
    Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1992 Feb; 33(4):273-9. PubMed ID: 1296435
    [Abstract] [Full Text] [Related]

  • 32. Candidate urinary biomarker discovery in ureteropelvic junction obstruction: a proteomic approach.
    Mesrobian HG, Mitchell ME, See WA, Halligan BD, Carlson BE, Greene AS, Wakim BT.
    J Urol; 2010 Aug; 184(2):709-14. PubMed ID: 20639044
    [Abstract] [Full Text] [Related]

  • 33. Urinary angiotensinogen as a novel marker of obstructive nephropathy in children.
    Taranta-Janusz K, Wasilewska A, Dębek W, Fiłonowicz R, Michaluk-Skutnik J.
    Acta Paediatr; 2013 Sep; 102(9):e429-33. PubMed ID: 23772991
    [Abstract] [Full Text] [Related]

  • 34. [Microproteinuria as a marker of renal damage in children].
    Chiaramonte C, Cigna RM, Cataliotti F.
    Minerva Urol Nefrol; 2002 Dec; 54(4):237-42. PubMed ID: 12536194
    [Abstract] [Full Text] [Related]

  • 35. Urinary polyomavirus: novel biomarker of congenital ureteropelvic junction obstruction.
    Assadi F, Mazaheri M.
    J Pediatr Urol; 2020 Feb; 16(1):107.e1-107.e5. PubMed ID: 31818677
    [Abstract] [Full Text] [Related]

  • 36. Congenital ureteropelvic junction obstruction: physiopathology, decoupling of tout court pelvic dilatation-obstruction semantic connection, biomarkers to predict renal damage evolution.
    Alberti C.
    Eur Rev Med Pharmacol Sci; 2012 Feb; 16(2):213-9. PubMed ID: 22428472
    [Abstract] [Full Text] [Related]

  • 37. Early alteration of urinary exosomal aquaporin 1 and transforming growth factor β1 after release of unilateral pelviureteral junction obstruction.
    Li ZZ, Zhao ZZ, Wen JG, Xing L, Zhang H, Zhang Y.
    J Pediatr Surg; 2012 Aug; 47(8):1581-6. PubMed ID: 22901921
    [Abstract] [Full Text] [Related]

  • 38. [Serum TGF-beta1 level in children with reflux nephropathy].
    Zajaczkowska M, Bieniaś B, Borzecka H, Sikora P, Majewski M, Bojarska-Junak A.
    Przegl Lek; 2006 Aug; 63 Suppl 3():121-3. PubMed ID: 16898507
    [Abstract] [Full Text] [Related]

  • 39. The effect of phosphodiesterase isoenzyme 5 inhibitors on ureteropelvic junction obstruction in rabbits.
    Wang HG, Yan XY, Cai YM, Wang HG, Chen JY.
    Urol Int; 2009 Aug; 83(3):316-22. PubMed ID: 19829033
    [Abstract] [Full Text] [Related]

  • 40. Urinary cytokines as markers of reflux nephropathy.
    Ninan GK, Jutley RS, Eremin O.
    J Urol; 1999 Nov; 162(5):1739-42. PubMed ID: 10524926
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.